ASCO GU 2026

Combination is the way to go - but how to select?

Encouraging new data in Prostate cancer

Patient Preferences for ARPI vs ADT in nmHSPC: A Global…

New Mode of Action in mCRPC

Actinium radioligand therapy

PSA-dynamics in TALAPRO-2

T-cell engager - first in human

Precision medicine for prostate cancer

Benefit of PARPi + ABI combination

EZH2 oral molecule to enhance ARPI

T-Cell-Engager

Radium-223 + Enzalutamid

Neoadjuvant therapy after molecular biopsy testing

Adjuvant therapy for RCC: Progress made, key questions…

Early SBRT shows safety, no added benefit

Belzutifan + Lenvatinib: A New Second-Line Approach in…

Upcoming new standard for adjuvant RCC

Treatment after immunotherapy in aRCC: always a complex…

Balancing efficacy and toxicity: the challenge in high…

Real World Data - RCC

New follow-up therapy with lenvatinib + belzutifan

New second-line option in mRCC

HIF based combination are here to stay

Combination therapy in adjuvant RCC

Adjuvant Pembrolizumab + Belzutifan vs Pembrolizumab

Long‑term effects of adjuvant therapy

Tratamiento después de la inmunoterapia en el carcinoma…

Closing the gap for platin eligibility

The future is bright, but complex

Important steps towards biomarker driven treatment of…

Perioperative EV+Pembrolizumab in MIBC

Perioperative EV + P - the new standard?!

pCR in MIBC under EV + P

Promising data - how to stratify the patients for the…

ctDNA testing: Who, how and how often?

ctDNA dynamics in the IMvigor011 trial

New perioperative standard for MIBC

MIBC - time for a historic paradigm shift?

ctDNA from plasma and urine in MIBC

New machanism of action in pts with UC

EV+P new SOC in MIBC

Urinary ctDNA vs. plasma ctDNA

Rethinking the use of HER2neu in routine clinical…

EV + P : nouveau standard de traitement pour le TVIM

Dinámica del ctDNA en el ensayo IMvigor011

Cáncer de vejiga músculo-invasivo: ¿es hora de un…